Developers of vapes for migraine, asthma will need to win over sceptics
August 09, 2024 by reuters.com
Developers of vapes for migraine, asthma will need to win over sceptics
A handful of North American companies which see potential for vape-like devices to ease migraines and respiratory diseases such as asthma have a long road to convince health authorities and patients that their products can be the future of inhaled medication. Two companies, Qnovia and MIIST Therapeutics, have developed vape-like devices based on technology used in existing medical nebulisers, which turns liquid medications into a fine mist. Another company, Greentank, says it has developed a way to vaporise substances via a heating chip that addresses safety concerns with current vapes and may offer a better way to treat ailments like migraines.
18.30% of the adult population are current smokers. There are approximately 48.7 million current smokers in United States 21.60% of men are current smokers but only 15.20% of women.
SOURCE: GSTHR
